CatalystPit
TerminalPit ConsensusInsidersPoliticiansInstitutionsNewsScreener

RVMDRevolution Medicines, Inc.

NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Last close $205.26 · 2026-09-30
ABOUT
ExchangeNASDAQ
SectorHealthcare
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Market cap$43.99B
CountryUSA
RECENT INSIDER TRADES
  • 2026-10-01 · Sandler Alan B. (Chief Development Officer) · SELL
  • 2026-10-01 · Sandler Alan B. (Chief Development Officer) · OTHER
INSTITUTIONAL OWNERSHIP
Institutional holders727
Shares held292,573,168
Value$42.71B
Percent of shares outstanding136.50%
As of quarter end2026-06-30
RECENT NEWS
  • Why is Revolution Medicines stock sliding today?
  • Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models
  • RVMD: Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
  • Revolution Medicines: Priced For A Label The Trial Didn't Test; Hold
  • Revolution Medicines’ CDO Sandler sells $1.2m in stock
CatalystPit
FeaturesComing soonPricingComing soonPrivacyTermsDisclaimerAffiliate TermsContact
2026 CATALYSTPIT · NOT FINANCIAL ADVICE · DELAYED FILINGS